Korea Investment CORP Cuts Stake in Taro Pharmaceutical Industries Ltd. (TARO)

Korea Investment CORP lowered its stake in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 28.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,000 shares of the company’s stock after selling 18,200 shares during the quarter. Korea Investment CORP owned approximately 0.11% of Taro Pharmaceutical Industries worth $5,184,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC grew its position in Taro Pharmaceutical Industries by 42.2% in the 2nd quarter. FMR LLC now owns 466,590 shares of the company’s stock valued at $52,286,000 after buying an additional 138,353 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Taro Pharmaceutical Industries by 35.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 178,392 shares of the company’s stock valued at $19,991,000 after buying an additional 46,570 shares during the last quarter. River Road Asset Management LLC grew its position in Taro Pharmaceutical Industries by 33.3% in the 2nd quarter. River Road Asset Management LLC now owns 65,470 shares of the company’s stock valued at $7,337,000 after buying an additional 16,350 shares during the last quarter. Aperio Group LLC grew its position in Taro Pharmaceutical Industries by 46.9% in the 2nd quarter. Aperio Group LLC now owns 50,826 shares of the company’s stock valued at $5,696,000 after buying an additional 16,233 shares during the last quarter. Finally, AHL Partners LLP grew its position in Taro Pharmaceutical Industries by 35.2% in the 2nd quarter. AHL Partners LLP now owns 26,604 shares of the company’s stock valued at $2,981,000 after buying an additional 6,923 shares during the last quarter. Institutional investors and hedge funds own 13.84% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://ledgergazette.com/2017/11/13/taro-pharmaceutical-industries-ltd-taro-holdings-reduced-by-korea-investment-corp.html.

A number of research firms recently weighed in on TARO. BidaskClub lowered shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. TheStreet lowered shares of Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE TARO) opened at $117.57 on Monday. Taro Pharmaceutical Industries Ltd. has a fifty-two week low of $94.00 and a fifty-two week high of $128.46. The company has a market capitalization of $4,760.00, a price-to-earnings ratio of 14.48 and a beta of 0.65.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply